A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naive, Non-Cirrhotic Subjects Infected With Chronic HCV Genotype 3
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2016
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 14 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 19 Nov 2015 Status changed from withdrawn prior to enrolment to not yet recruiting, as reported by ClinicalTrials.gov.
- 04 Nov 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.